Optos

Optos

Ultra-widefield retinal imaging devices for comprehensive eye examinations.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor

€0.0

round
N/A

€0.0

round
investor

€0.0

Valuation: €0.0

3.7x EV/Revenue

30.1x EV/EBITDA

round

N/A

Grant
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022
Revenues0000000000000000000000000000
% growth(11 %)(4 %)20 %(4 %)6 %--
EBITDA0000000000000000000000000000
% EBITDA margin32 %35 %40 %28 %35 %--
Profit0000000000000000000000000000
% profit margin24 %26 %31 %18 %23 %--
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue4 %64 %6 %8 %8 %--

Source: Company filings or news article

Notes (0)
More about Optos
Made with AI
Edit

Optos is a medical technology company that develops and manufactures ultra-widefield (UWF) retinal imaging devices for the early detection and treatment of eye diseases. The company was founded in 1992 by Douglas Anderson after his five-year-old son became blind in one eye when a retinal detachment was detected too late. Frustrated by the limitations of existing examination tools, Anderson, a healthcare product development expert, set out to create a patient-friendly device that could capture a comprehensive digital image of the entire retina.

The company's core product is the optomap®, a high-resolution digital image that captures approximately 82% (or 200 degrees) of the retina in a single, non-invasive scan. This provides a much wider view than traditional methods, which typically only show 15-20% of the retina at once. This enhanced visibility allows eye care professionals to detect diseases like diabetic retinopathy, glaucoma, age-related macular degeneration, and retinal tears that may originate in the periphery. More recent innovations integrate this UWF imaging with Optical Coherence Tomography (OCT) for detailed, cross-sectional views of the retina's layers. Optos operates on a business model that includes direct sales of its devices and service programs. It initially used a pay-per-patient model to increase accessibility for practitioners. Its client base includes independent optometrists and major eye clinics, such as those at Great Ormond Street Hospital and Harvard Medical Center.

Headquartered in Dunfermline, Scotland, Optos went public on the London Stock Exchange in 2006. In a strategic move to expand into the medical technology sector, Nikon Corporation acquired Optos in 2015 for approximately $400 million. This acquisition has allowed Optos to leverage Nikon's optical expertise and global presence to further its growth. As of March 2022, the company reported record annual revenues of $254 million and has installed over 22,000 devices worldwide.

Keywords: ultra-widefield retinal imaging, optomap, eye care diagnostics, medical imaging devices, ophthalmology, optometry, retinal detachment, diabetic retinopathy, glaucoma detection, Nikon healthcare, Douglas Anderson, Optical Coherence Tomography, OCT, medical technology, fundus imaging, eye examination, macular degeneration, peripheral retina, non-mydriatic, digital imaging

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo